Suppr超能文献

蛋白酶激活受体-2 特异性激动剂 2-氨基噻唑-4-基-LIGRL-NH2 和 6-氨基烟酰基-LIGRL-NH2 可刺激多种信号通路,在体外和体内诱导生理反应。

The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo.

机构信息

Department of Physiology, Bio5 Collaborative Research Institute, Arizona Respiratory Center, Arizona Health Sciences Center, Tucson, Arizona 85724, USA.

出版信息

J Biol Chem. 2011 May 27;286(21):19076-88. doi: 10.1074/jbc.M110.185264. Epub 2011 Apr 5.

Abstract

Protease-activated receptor-2 (PAR(2)) is one of four protease-activated G-protein-coupled receptors. PAR(2) is expressed on multiple cell types where it contributes to cellular responses to endogenous and exogenous proteases. Proteolytic cleavage of PAR(2) reveals a tethered ligand that activates PAR(2) and two major downstream signaling pathways: mitogen-activated protein kinase (MAPK) and intracellular Ca(2+) signaling. Peptides or peptidomimetics can mimic binding of the tethered ligand to stimulate signaling without the nonspecific effects of proteases. The most commonly used peptide activators of PAR(2) (e.g. SLIGRL-NH(2) and SLIGKV-NH(2)) lack potency at the receptor. However, although the potency of 2-furoyl-LIGRLO-NH(2) (2-f-LIGRLO-NH(2)) underscores the use of peptidomimetic PAR(2) ligands as a mechanism to enhance pharmacological action at PAR(2), 2-f-LIGRLO-NH(2) has not been thoroughly evaluated. We evaluated the known agonist 2-f-LIGRLO-NH(2) and two recently described pentapeptidomimetic PAR(2)-specific agonists, 2-aminothiazol-4-yl-LIGRL-NH(2) (2-at-LIGRL-NH(2)) and 6-aminonicotinyl-LIGRL-NH(2) (6-an-LIGRL-NH(2)). All peptidomimetic agonists stimulated PAR(2)-dependent in vitro physiological responses, MAPK signaling, and Ca(2+) signaling with an overall rank order of potency of 2-f-LIGRLO-NH(2) ≈ 2-at-LIGRL-NH(2) > 6-an-LIGRL-NH(2) ≫ SLIGRL-NH(2). Because PAR(2) plays a major role in pathological pain conditions and to test potency of the peptidomimetic agonists in vivo, we evaluated these agonists in models relevant to nociception. All three agonists activated Ca(2+) signaling in nociceptors in vitro, and both 2-at-LIGRL-NH(2) and 2-f-LIGRLO-NH(2) stimulated PAR(2)-dependent thermal hyperalgesia in vivo. We have characterized three high potency ligands that can be used to explore the physiological role of PAR(2) in a variety of systems and pathologies.

摘要

蛋白酶激活受体 2(PAR(2))是四种蛋白酶激活的 G 蛋白偶联受体之一。PAR(2) 表达于多种细胞类型,在细胞对内源性和外源性蛋白酶的反应中发挥作用。PAR(2) 的蛋白水解切割揭示了一个连接的配体,该配体激活 PAR(2) 和两个主要的下游信号通路:丝裂原活化蛋白激酶(MAPK)和细胞内 Ca(2+)信号。肽或肽类似物可以模拟连接配体的结合,从而刺激信号转导,而不会产生蛋白酶的非特异性影响。最常用的 PAR(2) 肽激活剂(例如 SLIGRL-NH(2)和 SLIGKV-NH(2))在受体上缺乏效力。然而,尽管 2-糠酰基-LIGRLO-NH(2)(2-f-LIGRLO-NH(2))的效力突出了使用肽拟似物 PAR(2)配体作为增强 PAR(2)药理学作用的机制,但 2-f-LIGRLO-NH(2)尚未得到彻底评估。我们评估了已知的激动剂 2-f-LIGRLO-NH(2)和最近描述的两种五肽肽拟似物 PAR(2)特异性激动剂,2-氨基噻唑-4-基-LIGRL-NH(2)(2-at-LIGRL-NH(2))和 6-氨基烟酰基-LIGRL-NH(2)(6-an-LIGRL-NH(2))。所有肽拟似物激动剂均刺激 PAR(2)依赖性体外生理反应、MAPK 信号转导和 Ca(2+)信号转导,效力总体顺序为 2-f-LIGRLO-NH(2)≈2-at-LIGRL-NH(2)>6-an-LIGRL-NH(2)>SLIGRL-NH(2)。由于 PAR(2) 在病理性疼痛状态中起主要作用,并测试肽拟似物激动剂在体内的效力,我们在与伤害感受相关的模型中评估了这些激动剂。所有三种激动剂均在体外激活伤害感受器中的 Ca(2+)信号转导,并且 2-at-LIGRL-NH(2)和 2-f-LIGRLO-NH(2)均在体内刺激 PAR(2)依赖性热痛觉过敏。我们已经描述了三种高效力配体,可用于探索 PAR(2)在各种系统和病理中的生理作用。

相似文献

4
Potent agonists of the protease activated receptor 2 (PAR2).蛋白酶激活受体 2(PAR2)的强效激动剂。
J Med Chem. 2011 Mar 10;54(5):1308-13. doi: 10.1021/jm1013049. Epub 2011 Feb 4.

引用本文的文献

7
Discovery of Novel Nonpeptidic PAR2 Ligands.新型非肽类PAR2配体的发现。
ACS Med Chem Lett. 2020 May 22;11(6):1316-1323. doi: 10.1021/acsmedchemlett.0c00154. eCollection 2020 Jun 11.

本文引用的文献

2
Potent agonists of the protease activated receptor 2 (PAR2).蛋白酶激活受体 2(PAR2)的强效激动剂。
J Med Chem. 2011 Mar 10;54(5):1308-13. doi: 10.1021/jm1013049. Epub 2011 Feb 4.
3
Signal transduction by protease-activated receptors.蛋白酶激活受体的信号转导。
Br J Pharmacol. 2010 May;160(2):191-203. doi: 10.1111/j.1476-5381.2010.00705.x.
8
Cellular and molecular mechanisms of pain.疼痛的细胞和分子机制。
Cell. 2009 Oct 16;139(2):267-84. doi: 10.1016/j.cell.2009.09.028.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验